Table 2.
Baseline demographics and disease characteristics.
| Baseline characteristic | IM (n = 30) | IM/HCQ (n = 32) |
|---|---|---|
| Median age, years (IQR) | 49.5 (42.0–66.0) | 50.0 (38.5–60.5) |
| Gender | ||
| Female | 33.3% | 28.1% |
| Male | 66.7% | 71.9% |
| Ethnicity | ||
| White | 93.1% | 100.0% |
| Afro/Caribbean | 6.9% | 0.0% |
| ECOG | ||
| 0 | 93.1% | 87.5% |
| 1 | 6.9% | 12.5% |
| IM dose at trial entry | ||
| 400 mg | 90.0% | 84.4% |
| 600 mg | 6.7% | 12.5% |
| 800 mg | 3.3% | 3.1% |
| Median time on IM pre-trial | 52.2 (32.8–110.0) | 49.7 (27.5–89.0) |
| Entry, months (IQR) | ||
| Response to imatinib at trial entry | ||
| Complete haematological response | 10.0% | 0.0% |
| Partial cytogenetic response | 3.3% | 0.0% |
| Major cytogenetic response | 3.3% | 6.3% |
| Complete cytogenetic response | 30.0% | 25.0% |
| Major molecular response | 50.0% | 62.5% |
| Deep molecular response | 0.0% | 0.0% |
| Unknown | 3.3% | 6.3% |
| Additional chromosomal abnormalities | 6.7%a | 9.4%b |
Data presented as percentage, or median (with IQR)
IM imatinib, HCQ hydroxychroroquine, IQR inter-quartile range (the 25th and 75th percentiles)
aOne patient on imatinib only had a variant Philadelphia chromosome translocation, and one had a deletion of chromosome 12
bOne patient on IM/HCQ had trisomy 21, one had a double Phliadelphia chromosome abnormality and one had a deletion of chromosome 9